Improved Glucose Variability in Elderly Case of Type 2 Diabetes (T2D) With Retinopathy by Vildagliptin/Metformin (Equmet)

Yamashita H, Bando H, Kawahito A, Sueki E, Aihara A, Fujii F, Kanazawa S, Ikezoe M, Fukushima N and Kato Y

Published on: 2024-10-17

Abstract

The case is 81-year-old male with type 2 diabetes (T2D) and cataract as mild simple retinopathy. He has T2D for 14 years, and HbA1c was increased to 9.4% in October 2003. His medication was changed from vildagliptin/metformin (EquMet LD) to EquMet HD with metformin 1000mg/day. The HbA1c was gradually and apparently decreased to 7.3% in 6 months. This combined oral hypoglycemic agent (OHA) has characteristic benefits for twice administration, controlling glucose control for all day, and stabilizing retinopathy. He continued petite low carbohydrate diet (petite LCD) that is most mild carbohydrate restriction, according to Japan LCD promotion Association (JLCDPA).